Summary
BeOne Medicines Ltd. reported a significant increase in revenue for the first quarter of 2026, reaching $1.51 billion, a 35.5% rise compared to the prior year period. This growth was primarily driven by strong sales of BRUKINSA®, which saw a 38.3% increase, and improved performance from TEVIMBRA® and in-licensed Amgen products. The company achieved positive net income of $227.4 million, a substantial improvement from the $1.3 million reported in the first quarter of 2025, translating to diluted EPS of $0.15. Operating expenses also increased, with R&D up 12.3% and SG&A up 20.9%, reflecting continued investment in pipeline development and commercial expansion. Despite these investments, income from operations surged to $250 million, a significant jump from $11.1 million in the prior year. The company ended the quarter with a strong cash position of $4.85 billion, and free cash flow turned positive at $160.5 million, indicating improving operational efficiency and financial health.
Financial Highlights
48 data points| Revenue | $1.51B |
| Gross Profit | $1.35B |
| R&D Expenses | $541.22M |
| SG&A Expenses | $555.10M |
| Operating Expenses | $1.10B |
| Operating Income | $249.90M |
| Net Income | $227.36M |
| EPS (Basic) | $0.16 |
| EPS (Diluted) | $0.15 |
| Shares Outstanding (Basic) | 1.44B |
| Shares Outstanding (Diluted) | 1.51B |
Key Highlights
- 1Total revenues increased by 35.5% to $1.51 billion in Q1 2026 compared to Q1 2025.
- 2BRUKINSA® global sales grew by 38.3% to $1.09 billion in Q1 2026.
- 3Net income improved dramatically to $227.4 million in Q1 2026, compared to $1.3 million in Q1 2025.
- 4Diluted Earnings Per ADS was $1.96 in Q1 2026, up from $0.01 in Q1 2025.
- 5Income from operations increased significantly by 2,151.0% to $249.9 million in Q1 2026.
- 6Free Cash Flow turned positive, reaching $160.5 million in Q1 2026, compared to negative $12.3 million in Q1 2025.
- 7Cash, cash equivalents, and restricted cash stood at $4.85 billion as of March 31, 2026.